INTRODUCTION {#sec1-1}
============

Atherosclerosis is the major cause of cardiovascular disease (CVD) and mortality globally.\[[@ref1]\] Very recent studies in Iran displayed the prevalence of the obesity,\[[@ref2]\] hypertension,\[[@ref3]\] and hypercholesterolemia\[[@ref4]\] are 30.9%, 23%, and 41.6%, respectively.

The statin group of drugs is widely used to treat hypercholesterolemia in patients at CVD risk.\[[@ref5]\] Statins inhibit the rate-limiting enzyme in cholesterol biosynthesis, hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase, and reduce serum low-density lipoprotein cholesterol (LDL-C) levels substantially.\[[@ref5]\] Further to their conventional lipid-modulating effects, statins possess so-called "pleiotropic" properties, which comprise improvement of endothelial function, antioxidant properties, anti-inflammatory properties, plaque stabilization, and inhibition platelet aggregation and thrombus formation.\[[@ref6]\] It has been reported that statins treatment may be associated with an improved Vitamin D status,\[[@ref7][@ref8][@ref9][@ref10]\] but this is not a consistent finding.\[[@ref11][@ref12][@ref13]\] There is emerging evidence suggesting that a decreased Vitamin D concentration might rise the possibility of several conditions including cancers and CVD.\[[@ref14][@ref15]\] If statins do have an impact on Vitamin D concentration this could be a reasonable elucidation of the described results of diminished risk of fracture; moreover, reduced risk of malignant illnesses in patients on this class of drugs.\[[@ref16]\] Thus, the present randomized controlled study set out to investigate the effects of treatment with simvastatin on serum Vitamin D in a group of dyslipidemic patients who were suitable for statin therapy.

METHODS {#sec1-2}
=======

Study design and participants {#sec2-1}
-----------------------------

A total of 102 male and female patients, age (20--88 old), who were not formerly receiving lipid-lowering drugs, registered from the Clinics of Ghaem Hospital, a teaching hospital located in Mashhad, Iran, between June 2010 and August 2012. The study was a randomized placebo-controlled cross-over trial; in this study, each patient took simvastatin or a placebo and next crossed over to the substitute. Inclusion criteria were based on the National Cholesterol Education Program-ATP III guidelines.\[[@ref17]\] Cardiovascular risk factors were defined as age more than 65 years old, receiving antihypertensive medication or systolic blood pressure of more than 140 mmHg or diastolic blood pressure of more than 90 mmHg, fasting blood glucose (FBG) greater than or equal to 126 mg/dL, positive family history of CVD, smoking, male sex, body mass index (BMI) more than or equal to 30 kg/m^2^. History of malignancy, recent history of infections, connective tissue disorders, treatment with immunomodulatory drugs (e.g., corticosteroids), liver or renal disease, leukocytosis (white blood cell count \>10,000/L), thrombocytosis (platelet count \>450,000 × 10^9^/L), and anemia (hematocrit \<40%) were the exclusion criteria. Each subject gave informed written consent to participate in the study, which had previously been approved by the Ethics Committee of Mashhad University of Medical Sciences (code: 88585). Each treatment period takes 1 month and there was a 14-day washout between the treatment periods. We asked the people to do not change the lifestyles during the trial also medications. At the first visit, patients were randomly assigned (random number tables) to one of the two treatment regimens. More details of the study have been published elsewhere.\[[@ref5]\] Fifty-one patients received 40 mg/day simvastatin for 1 month, and another group (51) received a placebo (same size and color with treatment capsules and filled with starch) for 30 days. After a further 2-week washout period, the patients crossed over to the other form of treatment. The sample size was based on the between-group mean comparison formula, according to the study conducted by Hu *et al*. with confidence interval of 95%, and power of 80% was calculated as for at least 45 subjects for each arm.\[[@ref18]\]

Vitamin D measurement {#sec2-2}
---------------------

Serum Vitamin D levels were measured using a competitive electroluminescence protein binding assay with the Roche Diagnostics Vitamin D total assay kit (Roche Diagnostics, Mannheim, Germany). The interday precision of this assay has been reported to be 4.9% and 1.9% at mean concentrations of 43.3 and 105 nmol/L, respectively, using the manufacturer\'s original control material.\[[@ref19]\]

Anthropometric and biochemical evaluation {#sec2-3}
-----------------------------------------

As previously described for each subject, weight, height, and BMI were measured two times (before randomization and at the end of each period observation) according to standard methods previously described.\[[@ref20]\] Blood sampling and biochemical analyses were done as previously fully described.\[[@ref20]\]

Statistical analysis {#sec2-4}
--------------------

SAS software (version 8) (SAS Institute Inc., Cary, NC) was used for statistical analysis. Data were expressed as means ± standard deviation or median and interquartile range. Value assessed for normality using the Kolmogorov--Smirnov test. *T*-test was used for a comparison between before and after treatments. For the analysis, the mixed-model analysis of variance for cross-over studies was used. The differences of these cross-over analyses were compared; they were normally distributed. Bivariate correlations between changes in Vitamin D and biochemical parameters were assessed. *P* ≤ 0.05 was reflected significant. The primary end-point was the change in serum fasting lipid profile and Vitamin D after treatment for 4 weeks. The secondary endpoints were changes in fasting blood glucose and high sensitive C-reactive protein (hsCRP).

RESULTS {#sec1-3}
=======

From 102 patients, who came into the trial, 25 (24.5%) dropped out; hence, the final sample size was 77 (78.2%). Noncompliance with the study protocol (*n* = 21), drug intolerance (*n* = 2), and relocation (*n* = 2) were the reasons for the drop-out. We failed to find any significant difference (*P* \> 0.05) when we compared the baseline data of biochemical and anthropometric factors before the first treatment period with those before the second treatment period. Moreover, no significant difference was found for age, sex, presence of hyperlipidemia, BMI, presence of hypertension, presence of diabetes, and smoking status between the two groups \[[Table 1](#T1){ref-type="table"}\].

###### 

Comparison of baseline characteristics of subjects
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Effects of simvastatin versus placebo on Vitamin D {#sec2-5}
--------------------------------------------------

Statin therapy did not have a significant effect on serum levels of Vitamin D in either the statin-placebo or the placebo-statin group \[*P* = 0.90, [Table 2](#T2){ref-type="table"}\]. Bivariate correlations were assessed between baseline values of Vitamin D and other evaluated biochemical parameters (total cholesterol, LDL-C, high-density lipoprotein cholesterol \[HDL-C\], triglycerides \[TGs\], FBG, and hs-CRP), as well as between changes in Vitamin D and other parameters during each study period. No significant correlation was found between baseline values of Vitamin D and evaluated biochemical parameters (*P* \> 0.05) \[[Table 3](#T3){ref-type="table"}\]. Furthermore, significant correlations were observed between serum Vitamin D and the following parameters: FBG (statin-placebo group, second period; *P* \< 0.01), TGs (placebo-statin group, second period; *P* \< 0.05 and statin-placebo first period; *P* \< 0.01), LDL-C (placebo-statin group, first period; *P* \< 0.05), and HDL-C (statin-placebo group, first period; *P* \< 0.05) \[[Table 4](#T4){ref-type="table"}\].

###### 

Effect of simvastatin versus placebo on Vitamin D status
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###### 

Correlation between baseline biochemical parameters and Vitamin D in placebo-statin group and statin-placebo group
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###### 

Correlation between changes in biochemical parameters in two periods of placebo-statin group and statin-placebo
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DISCUSSION {#sec1-4}
==========

The aim of this study was to investigate the impact of simvastatin therapy on serum Vitamin D levels in dyslipidemic patients. Our results showed that simvastatin therapy for 4 weeks (40 mg/day) does not alter serum Vitamin D levels. Previous investigations on the impact of statin therapy on circulating Vitamin D levels have been inconsistent. While atorvastatin\[[@ref21]\] and rosuvastatin\[[@ref22][@ref23]\] have been shown to raise 25(OH) Vitamin D levels, there are reports with opposite findings showing that HMG-CoA reductase inhibitors do not affect serum Vitamin D concentrations.\[[@ref23]\] It is not well known how statins might affect Vitamin D concentration, and numerous potential mechanisms have been put forward.\[[@ref24]\] The first and by far the most plausible mechanism regards to the common metabolic fate of statins and Vitamin D. Both 25(OH) Vitamin D, and statins are metabolized in the liver by CYP3A4.\[[@ref24]\] Therefore, the occupation of the active site of this enzyme by statins may account for the elevated 25(OH) Vitamin D levels reported in some trials. Ertugrul *et al*. indicated that rosuvastatin (40 mg/day) as monotherapy and rosuvastatin (10 mg/day) plus fenofibrate (200 mg/day) or omega-3 fatty acids (2 g/day) cause substantial elevations in the 25(OH) Vitamin D levels (53%, 64%, and 61%, respectively).\[[@ref25]\] Moreover, in study by Thabit *et al*., they found that simvastatin and atorvastatin, at any dose for duration of more than 1 year, have no additive effect on 25(OH)D level.\[[@ref26]\] Unlike rosuvastatin and atorvastatin, no considerable change in Vitamin D concentration has been reported in patients that used fluvastatin.\[[@ref23]\] A new randomized controlled trial could not prove an effect of 12 months simvastatin therapy (40 mg/day) on Vitamin D concentration.\[[@ref27]\]

The physicochemical characteristics of different statins may also play a role in their differential effects on Vitamin D metabolism.\[[@ref22][@ref23]\] The present study had several limitations. First, the study design did not allow adequate time for a new steady-state level of Vitamin D, did not control or report Vitamin D intake, did not analyze for seasonal effects, and the 25(OH) Vitamin D assay was not the MS/MS gold standard. The main strength of the present study was being based on a robust placebo-controlled and cross-over design as well as being conducted in a target population, not under concomitant lipid-lowering therapy. Therefore, many of the confounding factors that may generally affect lipid alterations were eliminated from the present trial.

CONCLUSIONS {#sec1-5}
===========

We found that statin had no significant effect on serum Vitamin D status in dyslipidemic patients. Further research might explore the effects of long-term statin therapy on Vitamin D status.
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